Weight-Adjusted Dosing of 3-OHB in Patients With Chronic Heart Failure
- Conditions
- Heart FailureKetosis
- Interventions
- Dietary Supplement: KetoneAid KE4 Pro MonoesterDietary Supplement: Science in Sport Go Enegy
- Registration Number
- NCT04594265
- Lead Sponsor
- University of Aarhus
- Brief Summary
We aim to investigate the hemodynamic effects of weight-adjusted dosing of ketone monoester en patients with chronic heart failure.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 8
Not provided
Diabetes or HbA1c >48 mmol/mol, significant cardiac valve disease, severe stable angina pectoris, severe comorbidity as judged by the investigator, inability to give informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Ketone Monoester KetoneAid KE4 Pro Monoester Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US) 0.5 g/kg (max 50 g) Placebo Treatment Science in Sport Go Enegy Maltodextrin-based placebo (Science In Sport, UK) in isocaloric dose to the experimental arm. Ketone Monoester in presence of low-dose insulin clamp KetoneAid KE4 Pro Monoester Same as experimental arm, but in the presence of a low-dose insulin clamp to suppress free fatty acid metabolism
- Primary Outcome Measures
Name Time Method Cardiac Output (L/min) 3 hours - Area under the curve Change in Cardiac output measured by Swann-Ganz Catherization during study period,
- Secondary Outcome Measures
Name Time Method Blood Ketones 3 hours Change in blood Ketones measured by venous blood samples
Blood pH 3 hours Change in venous blood pH during the study period
Left Ventricular Ejection Fraction 3 hours - Area under the curve Change in LVEF measured by echocardiography during study periode
Trial Locations
- Locations (1)
Aarhus University Hospital
🇩🇰Aarhus, Denmark